Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection.
Sheth S, Mukherjea D, Rybak LP, Ramkumar V. · 2017
Read Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection. by Sheth S, Mukherjea D, Rybak LP, Ramkumar V. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5663723.txt.
Introduction
Sheth and co-authors review how the cancer drug cisplatin damages hearing. Their review appeared in Frontiers in Cellular Neuroscience. Hearing loss appeared early in cisplatin use. Excess reactive oxygen species harm cochlear cells. Later work added inflammation to the picture. The review traces each mechanism.
Several protection strategies follow from the biology. Antioxidants can scavenge the harmful species. Certain receptors reduce inflammation in animal tests. Blocking the TRPV1 channel also protected hearing. Transporter inhibitors can keep cisplatin out. DNA damage and cell death pathways offer targets too. The authors gather recent drug approaches. Each approach grows from a known mechanism.
Catalog record
| CREATOR | Sheth S, Mukherjea D, Rybak LP, Ramkumar V. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection By Sandeep Sheth, Debashree Mukherjea, Leonard P Rybak, Vickram Ramkumar Published in: Frontiers in Cellular Neuroscience DOI: 10.3389/fncel.2017.00338 ABSTRACT Abstract Evidence of significant hearing loss during the early days of use of cisplatin as a chemotherapeutic agent in cancer patients has stimulated research into the causes and treatment of this side effect. It has generally been accepted that hearing loss is produced by excessive generation of reactive oxygen species (ROS) in cell of the cochlea, which led to the development of various antioxidants as otoprotective agents. Later studies show that ROS could stimulate cochlear inflammation, suggesting the use of anti-inflammatory agents for treatment of hearing loss. In this respect, G-protein coupled receptors, such as adenosine A1 receptor and cannabinoid 2 receptors, have shown efficacy in the treatment of hearing loss in experimental animals by increasing ROS scavenging, suppressing ROS generation, or by decreasing inflammation. Inflammation could be triggered by activation of transient receptor potential vanilloid 1 (TRPV1) channels in the cochlea and possibly other TRP channels. Targeting TRPV1 for knockdown has also been shown to be a useful strategy for ensuring otoprotection. Cisplatin entry into cochlear hair cells is mediated by various transporters, inhibitors of which have been shown to be effective for treating hearing loss. Finally, cisplatin-induced DNA damage and activation of the apoptotic process could be targeted for cisplatin-induced hearing loss. This review focuses on recent development in our understanding of the mechanisms underlying cisplatin-induced hearing loss and provides examples of how drug therapies have been formulated based on these mechanisms. Keywords: cisplatin, ototoxicity, otoprotection, oxidative stress, apoptosis, antioxidants, anti-inflammatory agents CISPLATIN OTOTOXICITY Cisplatin is a widely used and effective drug for the treatment of solid tumors ranging from ovarian, lung, head, and neck to testicular cancer. Dose limiting side effects, such as ototoxicity, neurotoxicity, and nephrotoxicity, are generally encountered with a majority of patients treated with cisplatin-based chemotherapy. Methods to increase diuresis, such as hydration, have been shown to reduce nephrotoxicity. However, to date no effective FDA approved treatment for ototoxicity is available. Cisplatin-induced hearing loss is primarily in the high frequency range. It is bilateral and permanent and severely affects the quality of life for cancer patients. The incidence of cisplatin-induced hearing loss in children ranges from 22 to 77% (Knight et al., 2005; Kushner et al., 2006; Coradini et al., 2007). This range reflects hearing loss observed with the different doses and duration of cisplatin treatment in addition to the different age groups of the patients who were treated. Accordingly, children show greater risk for developing hearing loss following cisplatin treatment than adults (Knight et al., 2005; Kushner et al., 2006; Gurney et al., 2007). Hearing loss is especially difficult for children who are undergoing treatment for brain tumors, such as neuroblastoma. It could affect early speech development and hamper social integration. Development of effective therapies for treating hearing loss is therefore of primary importance. Several approaches have been undertaken over the past two decades to treat cisplatin ototoxicity. These include the use of localized or systemic administration of antioxidants or drugs which activate endogenous antioxidant systems. Cisplatin induces apoptosis of hair cells through activation of mitochondrial pathway which can be targeted to inhibit cell death. Another approach involves using anti-inflammatory agents which target the pro-inflammatory mechanisms associated with cisplatin treatment in the cochlea. Recent insights into the entry processes of cisplatin in hair cells and other cells in the cochlea should stimulate the development of drugs which specifically block entry of drugs into these cells without affecting cisplatin entry into cancer cells. This report reviews the currently accepted mechanisms underlying cisplatin-induced damage or death to cochlear cells and highlights how these mechanisms could guide the future development of effective otoprotective agents. COCHLEAR ROS GENERATION AND ANTIOXIDANT DEFENSE SYSTEM The normal function of the cochlea requires its high metabolic activity in areas such as the stria vascularis, spiral ligament, and spiral prominence (Salt et al., 1987; Ryan, 1988). This high metabolic activity leads to leakage of electrons from the mitochondrial respiratory chain which can react with oxygen (O2) to form superoxide (). Environmental stimuli which increase the metabolic activity of the cochlea, such as loud noise, are expected to increase oxidative stress in the cochlea. The metabolic demand on the cochlea renders it very sensitive to hypoxic events and ischemia-reperfusion injuries (Seidman et al., 1991). Ototoxic drugs, such as cisplatin have been shown to increase the generation of reactive oxygen species (ROS) (Clerici and Yang, 1996; Kopke et al., 1997) by either stimulating enzyme systems linked to this process or by inactivating antioxidant systems (Church et al., 1995; Rybak et al., 1995). Rats injected with cisplatin demonstrate reduced cochlear glutathione (GSH) and antioxidant enzyme activities (Ravi et al., 1995). A primary target of cisplatin for generation of ROS is the NOX3 NADPH oxidase system (Banfi et al., 2004). NOX3 is induced by cisplatin and knockdown of this enzyme by trans-tympanic delivery of siRNA protects against cisplatin-induced ototoxicity (Mukherjea et al., 2010). Since NOX3 is localized primarily to the cochlea, systemic administration of inhibitors of NOX3 could effectively reduce enzyme activity and treat hearing loss. Another active ROS generating system in the cochlea is xanthine oxidase. This enzyme converts hypoxanthine (a metabolite derived from the breakdown of adenosine by adenosine deaminase) to uric acid. Inhibition of this enzyme by allopurinol contributes to reductions in cisplatin-induced ototoxicity and nephrotoxicity when administered with ebselen, a glutathione peroxidase (GSH.Px) mimetic (Lynch et al., 2005). The cochlea possesses an efficient antioxidant defense system. This includes antioxidants such as vitamin C, vitamin E, and low molecular weight thiols, such as GSH (Kopke et al., 1999). Studies in the guinea pig cochlea show that the highest levels of GSH are present in the basal and intermediate cells of the stria vascularis and in cells of the spiral ligament (Usami et al., 1996). This distribution matches well with the distribution of glutathione S-transferase (el Barbary et al., 1993), an enzyme which conjugates and detoxifies xenobiotics (such as cisplatin). Increased levels of glutathione S-transferase in cancer cells can aid in the inactivation of cisplatin and contribute to resistance to cisplatin in the cochlea. In addition, the cochlea expresses several antioxidant enzymes, which include superoxide dismutase (SOD), GSH.Px, and catalase (CAT). SOD catalyzes the conversion of to H2O2 and O2 while CAT converts H2O2 to O2 and H2O. GSH.Px reduces H2O2 and possibly other peroxides. The enzyme GSH.Px also catalyzes the conversion of reduced GSH to its oxidized form (GSSG), in the process of detoxifying H2O2. In addition, glutathione reductase (GR) is important for the defense against ROS by aiding in the regeneration of GSH from GSSG (Figure 1). Two forms of SOD are expressed in the cochlea. A Cu/Zn isoform of SOD is localized in the cytosol, while a Mn-regulated isoform (Mn-SOD) is localized to the mitochondria (Yao and Rarey, 1996). Mn-SOD is localized to metabolically active sites in the cochlea such as stria vascularis, spiral ligament, spiral prominence, spiral limbus, and organ of Corti (Lai et al., 1996). Activities of SOD were higher in the subcellular fractions of stria vascularis and spiral ligament compared to the organ of Corti (Pierson and Gray, 1982; Yao and Rarey, 1996).